Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.
Leveille E, Kothari S, Cosgun KN, Mlynarczyk C, Müschen M. Leveille E, et al. Among authors: kothari s. Cancer Discov. 2024 Sep 4;14(9):1577-1580. doi: 10.1158/2159-8290.CD-24-0644. Cancer Discov. 2024. PMID: 39228298
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.
Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ. Torka P, et al. Among authors: kothari sk. Blood Adv. 2020 Jan 28;4(2):253-262. doi: 10.1182/bloodadvances.2019000875. Blood Adv. 2020. PMID: 31945157 Free PMC article.
A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome.
Güney E, Lucas CG, Qi Z, Yu J, Zhang R, Ohgami RS, Rubenstein JL, Boué DR, Schafernak K, Wertheim GB, Dahiya S, Giulino-Roth L, Attarbaschi A, Barth MJ, Kothari S, Abla O, Cohen AL, Mendez JS, Bollen A, Perry A, Tihan T, Pekmezci M, Solomon DA, Wen KW. Güney E, et al. Among authors: kothari s. Blood Adv. 2022 May 24;6(10):3189-3193. doi: 10.1182/bloodadvances.2021006018. Blood Adv. 2022. PMID: 35157770 Free PMC article. No abstract available.
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ. Zayac AS, et al. Among authors: kothari sk. Blood Adv. 2023 Nov 14;7(21):6381-6394. doi: 10.1182/bloodadvances.2023009731. Blood Adv. 2023. PMID: 37171397 Free PMC article.
Postibrutinib relapse outcomes for patients with marginal zone lymphoma.
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Epperla N, et al. Among authors: kothari s. Blood Adv. 2023 Jan 10;7(1):88-91. doi: 10.1182/bloodadvances.2022008634. Blood Adv. 2023. PMID: 36269847 Free PMC article. No abstract available.
1,184 results